Vincristine (Oncovin®) is a mitosis-inhibiting chemotherapy agent derived as an alkaloid from the Catharanthus roseus (Madagascar periwinkle), formerly Vinca rosea.
Vincristine has also been used in multidrug regimens such as DAV protocol (doxorubicin, dacarbazine and vincristine combination). With this protocol, doxorubicin and dacarbazine are administered on day 1 while vincristine is administered on days 8 and 15, repeated every 21 days for a maximum of six cycles or until disease progression. This regimen has shown efficacious (50% response rate; 125 day survival) for treatment of canine hemangiosarcoma.
Toxicities to this drug have been reported, specifically causing acute renal failure, but also causes respiratory distress (due to pulmonary oedema), peripheral neuropathy, hyponatremia, constipation and alopecia.
- Van den Steen N et al (2012) Rectal lymphoma in 11 dogs - a retrospective study. J Small Anim Pract 53(10):586-591
- Dervisis NG et al (2011) Treatment with DAV for advanced-stage hemangiosarcoma in dogs. J Am Anim Hosp Assoc 47(3):170-178
- Krugman L et al (2012) Vincristine-induced central neurotoxicity in a collie homozygous for the ABCB1Δ mutation. J Small Anim Pract 53(3):185-187